Shunichiro Onishi

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki et al. · The Lancet Diabetes & Endocrinology · 2017 · 300 citations

Non-pharmacological Intervention, Diabetes Management, Cardiovascular Disease +9

The roles of transforming growth factor-β and Smad3 signaling in adipocyte differentiation and obesity

Yuya Tsurutani, Masaki Fujimoto, Minoru Takemoto et al. · Biochemical and Biophysical Research Communications · 2011 · 102 citations

Obesity, Metabolic Syndrome, Systems Biology +12

The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study

Morito Mezawa, Minoru Takemoto, Shunichiro Onishi et al. · BioFactors · 2012 · 43 citations

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi et al. · Diabetes Obesity and Metabolism · 2019 · 39 citations · Full text

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with α‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (<scp>SUCCESS</scp>‐2): a multicenter, randomized, open‐label, non‐inferiority trial

K. Kobayashi, Hidetaka Yokoh, Yasunori Sato et al. · Diabetes Obesity and Metabolism · 2014 · 25 citations

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +15